Composition of prodigiosins and oxacillin or derivatives of oxacillin, application of composition and medicine containing composition

A technology of oxacillin and prodigiosin, applied in the field of medicine, can solve the problems of decreased sensitivity, affected treatment effect of patients, recurrent disease and the like

Active Publication Date: 2021-04-02
珠海中科先进技术研究院有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, under the selection pressure of antibiotics, the sensitivity of methicillin-resistant Staphylococcus aureus to antibiotics continues to decline, leading to recurrent disease and affecting the treatment effect of patients.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition of prodigiosins and oxacillin or derivatives of oxacillin, application of composition and medicine containing composition
  • Composition of prodigiosins and oxacillin or derivatives of oxacillin, application of composition and medicine containing composition
  • Composition of prodigiosins and oxacillin or derivatives of oxacillin, application of composition and medicine containing composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] The composition of embodiment 1 prodigiosin and oxacillin or its derivatives is to the minimum inhibitory concentration (MIC) of methicillin-resistant Staphylococcus aureus (MRSA)

[0021] Inoculate the MRSA bacterial suspension in LB medium, cultivate overnight at 37°C, correct the bacterial solution to make it equivalent to the 0.5 McFarland turbidimetric standard, and then dilute it with LB medium at 1:200 for later use.

[0022] Prepare 11 test tubes, take a test tube to prepare 2ml of prodigiosin LB medium solution with a working concentration of 50μg / ml, take 1ml and add it to the test tube containing 1ml LB medium, mix well, suck out 1ml and add it to the third tube , and so on to the 11th tube, suck out 1ml and discard, the final content of prodigiosin in each test tube is 50, 25, 12.5, 6.25, 3.125, 1.562, 0.781, 0.391, 0.195, 0.098, 0.049μg / ml.

[0023] Prepare an oxacillin sodium LB medium solution with a working concentration of 50 μg / ml according to the ab...

Embodiment 2

[0038] Example 2 Preparation of Drugs for the Treatment of Methicillin-resistant Staphylococcus aureus Infectious Diseases

[0039] The medicine for treating infectious diseases caused by methicillin-resistant Staphylococcus aureus comprises the composition of prodigiosin and oxacillin or its derivatives in Example 1.

[0040] Preferably, a combination of one or more of pharmaceutically acceptable carriers, excipients, diluents and adjuvants is also included.

[0041] Preferably, the medicine is any one of compound tablet, compound capsule or compound powder.

[0042]Preferably, the drug is a composite tablet, and every 300g of the composite tablet is composed of the following raw material components: 9g of the composition of prodigiosin and oxacillin or its derivatives, 0-200g of starch, pre- Gelatinized starch 0-200g, talcum powder 3g, hydroxypropyl cellulose 0-58g, carboxymethylcellulose sodium 0-58g, carboxymethyl starch sodium 0-30g and cross-linked polyvinylpyrrolidone ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a composition of prodigiosins and oxacillin or derivatives of the oxacillin. The mass ratio of the prodigiosins to the oxacillin or the derivatives of the oxacillin is (1-2.55): 1. The invention further provides application of the composition in preparation of drugs for treating infectious diseases caused by methicillin-resistant staphylococcus aureus, and also provides amedicine for treating the infectious diseases caused by methicillin-resistant staphylococcus aureus. The antibacterial effect of the composition and the medicine containing the composition is obviously higher than that of two single components.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a composition of prodigiosin, oxacillin or derivatives thereof, its application and the medicine containing it. Background technique [0002] Prodigiosins (PG) is a natural red pigment with a polypyrrole ring, which is a secondary metabolite produced by some actinomycetes, Serratia and other bacteria. It was first discovered by Amok and Harashima in 1929. It is isolated from Serratia marcescens. In recent years, many scholars have found that prodigiosin is a very potential antibacterial drug. Antibacterial tests in vitro show that prodigiosin has good antibacterial effect on Bacillus subtilis, Escherichia coli, Pseudomonas aeruginosa, etc., and has certain drug potential. [0003] Methicillin-resistant Staphylococcus aureus (MRSA) is one of the main pathogens of hospital and community infections, often causing acute suppurative pneumonia in adults and children. Methicillin-re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/431A61K31/4025A61K9/14A61K9/20A61K9/48A61K47/36A61K47/38A61P31/04
CPCA61K31/4025A61K31/431A61K9/2059A61K9/4866A61K9/146A61P31/04A61K2300/00
Inventor 徐畅陈婉玲高飞谢桦函李志鹏姜长安
Owner 珠海中科先进技术研究院有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap